Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 1.34 +0.05 (+4.11%)
As of 05:34 AM Eastern
Compare

CLBX vs. REDX, ETX, HEMO, HVO, and POLB

Should you buy Cellbxhealth stock or one of its competitors? MarketBeat compares Cellbxhealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellbxhealth include Redx Pharma (REDX), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), hVIVO (HVO), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to Redx Pharma?

Cellbxhealth (LON:CLBX) and Redx Pharma (LON:REDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Cellbxhealth has higher earnings, but lower revenue than Redx Pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M13.26N/A-£5.51N/A
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A

Cellbxhealth's return on equity of 0.00% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Redx Pharma N/A -180.80%-43.95%

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Redx Pharma'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Redx Pharma Neutral

Summary

Redx Pharma beats Cellbxhealth on 4 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to e-therapeutics?

e-therapeutics (LON:ETX) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
e-therapeutics Neutral
Cellbxhealth Neutral

Cellbxhealth has higher revenue and earnings than e-therapeutics. Cellbxhealth is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
e-therapeutics£295K0.00-£10.06M-£0.02N/A
Cellbxhealth£1.15M13.26N/A-£5.51N/A

26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cellbxhealth's return on equity of 0.00% beat e-therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
e-therapeuticsN/A -38.75% -29.10%
Cellbxhealth N/A N/A N/A

Summary

Cellbxhealth beats e-therapeutics on 4 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Hemogenyx Pharmaceuticals?

Cellbxhealth (LON:CLBX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellbxhealth's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Cellbxhealth has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M13.26N/A-£5.51N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Cellbxhealth beats Hemogenyx Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to hVIVO?

hVIVO (LON:HVO) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
hVIVO Neutral
Cellbxhealth Neutral

hVIVO has higher revenue and earnings than Cellbxhealth. hVIVO is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M1.08£17.84M-£0.87N/A
Cellbxhealth£1.15M13.26N/A-£5.51N/A

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 104.08%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts plainly believe hVIVO is more favorable than Cellbxhealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Cellbxhealth
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cellbxhealth has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Cellbxhealth's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Cellbxhealth N/A N/A N/A

Summary

hVIVO beats Cellbxhealth on 8 of the 12 factors compared between the two stocks.

How does Cellbxhealth compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cellbxhealth's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Cellbxhealth N/A N/A N/A

Cellbxhealth has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Cellbxhealth£1.15M13.26N/A-£5.51N/A

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Cellbxhealth Neutral

Summary

Cellbxhealth beats Poolbeg Pharma on 4 of the 7 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£15.27M£3.54B£6.86B£2.82B
Dividend YieldN/A3.78%2.59%6.15%
P/E Ratio-0.247.38282.30368.45
Price / Sales13.261,201.52564.9883,500.12
Price / CashN/A44.8028.6027.89
Price / BookN/A16.7810.927.06
Net IncomeN/A-£12.56M£3.49B£5.89B
7 Day Performance4.51%-1.79%-0.64%6.48%
1 Month Performance-12.39%-8.41%-5.24%0.22%
1 Year PerformanceN/A48.37%61.98%64.32%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 1.34
+4.1%		N/AN/A£15.27M£1.15MN/AN/A
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 748
+2.9%		N/A+296.2%£50.86MN/AN/A14
HVO
hVIVO
N/AGBX 7.20
-4.0%		GBX 15
+108.3%		-26.0%£49.57M£46.77MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel